Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 121 resultados

PrIMAVeRa: Predicting the Impact of Monoclonal Antibodies Vaccines on Antimicrobial Resistance Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-speci...
2021-11-09 - 2026-10-31 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado

FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado

BEAMER: BEhavioral and Adherence Model for improving quality health outcomes and cost Effectiveness of heal... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outco...
2021-09-27 - 2026-08-31 | Financiado

RealHOPE: Real World Handling of Protein Drugs Exploration Evaluation and Education Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage RealHOPE will create an understanding of the real-life handling of protein drugs in hospital pharmacy, clinics and in the hands of patients...
2021-07-05 - 2025-06-30 | Financiado

HIPPOCRATES: Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage Psoriatic Arthritis (PsA) is a clinically heterogeneous disease associated with diminished quality of life. Early diagnosis is challenging a...
2021-06-29 - 2026-06-30 | Financiado

PROMISE: Preparing for RSV Immunisation and Surveillance in Europe Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage RSV causes severe disease in the very young and elderly and results in substantial healthcare costs. In the last 4 years, substantial progre...
2021-05-21 - 2024-04-30 | Financiado

REsolution: Add medical genetic solutions to RESOLUTE REsolution Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-22-single-stage Solute carriers (SLCs) are the largest family of membrane transporters encoded in the human genome and their role in trafficking nutrients,...
2021-05-18 - 2023-12-31 | Financiado

BIGPICTURE: Central Repository for Digital Pathology Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado

Gravitate-Health: Gravitate Health Empowering and Equipping Europeans with health information for Active Personal Hea... The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsiv...
2020-11-12 - 2025-10-31 | Financiado

ARDAT: Accelerating Research Development for Advanced Therapies Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado

SISAQOL-IMI: Establishing international standards in the analysis of patient reported outcomes and health related... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is genera...
2020-11-09 - 2024-12-31 | Financiado

H2O: H2O Health Outcomes Observatory Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Patients' outcomes and experience of health care can be improved through the systematic capture and use of information from their perspectiv...
2020-09-30 - 2025-09-30 | Financiado

CARE: Corona Accelerated R D in Europe Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2020-21-single-stage The Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as the largest global health threat to humanity in thi...
2020-08-07 - 2025-03-31 | Financiado

HARMONY PLUS: HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY PLUS Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-19-single-stage Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be e...
2020-05-26 - 2024-03-31 | Financiado

SOPHIA: Stratification of Obesity Phenotypes to Optimize Future Therapy Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage SOPHIA will optimise the future treatment of obesity. The challenge is that clinicians, payers and patients view obesity as a failure of sel...
2020-05-26 - 2025-05-31 | Financiado

EUbOPEN: EUbOPEN Enabling and Unlocking biology in the OPEN Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2019-17-two-stage The EUbOPEN partnership of excellence will aim to generate the largest freely available set of high-quality chemical inhibitors for human pr...
2020-05-11 - 2025-04-30 | Financiado

IDEA-FAST: Identifying Digital Endpoints to Assess FAtigue Sleep and acTivities in daily living in Neurodegene... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Fatigue and sleep disturbances are two common and disabling symptoms that affect patients with neurodegenerative disorders (NDD) and immune-...
2019-12-18 - 2026-04-30 | Financiado

ImmUniverse: Better control and treatment of immune mediated diseases by exploring the universe of microenvironme... Pfizer RD UK Limited participó en un H2020: H2020-JTI-IMI2-2018-15-two-stage Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enorm...
2019-12-17 - 2024-12-31 | Financiado